retatrutide low energy Diagram showing the mechanism of action of Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

A study published in March 2023 evaluating 20 44 year olds from 2009 to 2020 discovered the prevalence of diabetes grew from 3% to 4.1% and the incidence of obesity increased from 32.7% to 40.9%

For researchers managing metabolic health beyond the number on the scale, this benefit has no equivalent in tirzepatide protocols

It does not appear to suppress sperm production the way exogenous testosterone does, and that is a real and meaningful difference

Thyroid blood tests The Science: GLP-1 and Thyroid Cancer Risks The most common concern regarding GLP-1 medications and the thyroid is the risk of thyroid cancer

The safety profile has been favorable through several years of real-world use